Sam Collins

Sam Collins

Sam Collins is  InvestorPlace.com’s Chief Technical Analyst. He has more than four decades of experience in Wall Street firms.

In addition to providing fundamental and technical analysis for InvestorPlace.com, he provides FREE daily market commentary each trading day via the Daily Trader’s Alert. The Daily Trader’s Alert contains his Daily Market Outlook PLUS a Trade of the Day.

Sam served as a regular army captain serving in West Germany during the Berlin Wall Crisis before joining Merrill Lynch as a futures broker. Since then, he has been a financial adviser, branch manager, regional manager and certified portfolio manager with national and regional securities firms. While he retired in October 2009, during his career, he received recognition and numerous awards.

Sam used technical analysis as a timing and selection technique with portfolios that he managed. He developed a specific technical analysis technique and timing system called the Collins Bollinger Reversal (CBR) that has received national recognition, and he has appeared on local and national TV as a financial commentator.

As an equity specialist and technician, he uses technical analysis as a selection technique along with fundamental analysis. As a value buyer, his goal is to find companies with outstanding management, unique products and strong financials that have not yet been driven to unreasonable prices. His CBR system helps him to screen vast amounts of data for stocks that meet those standards.

Sam is also a member of the NASD Board of Arbitrators.

Recent Articles

Traders Should Move Quickly on 3D Systems

3D Systems (DDD) broke from a compound top on high volume.

Whatever Happens, Don’t Take This Week Too Seriously

The final week of August is usually accompanied by very light volume, which often contributes to high volatility.

The Pop in Bond Prices Is Meaningless

Investors who own bonds and their equivalents will have a tough time making money in the foreseeable future.

It’s Time to Cash In on This Huge Biotech Winner

NPS Pharmaceuticals (NPSP) has risen 159% since my initial recommendation.

The Bear Market Isn’t Here Yet, But…

Resistance will prove tough to overcome and risk is incredibly high.